A real-world study looking at how people respond outside of clinical trials found that non-response rates may be somewhat higher in everyday practice, with 10 to 30% of patients achieving less than 5% total body weight loss, depending on the dose and individual factors involved (4)
Next week we will be in Pittsfield (Thursday, 10/9), at the Holiday Inn & Suites Pittsfield-Berkshires at 1PM) and West Springfield (Friday, 10/9) at the Storrowton Tavern at 11AM
Post-translational modifications, especially those in the DNA binding domain of FOXO4 protein, appear to modify its functionality as a transcription factor and regulation of pathways such as apoptosis, cellular senescence, insulin signaling, and senescence
Expanded Indications and Emerging Uses For GLP-1 Receptor Agonists As of April 2025, GLP-1 receptor agonists continue to evolve beyond their original use in type 2 diabetes and obesity management